Can I use capecitabine and oxaliplatin (CAPOX) as a chemotherapy regimen?

Yes, capecitabine and oxaliplatin (CAPOX) is an established and effective chemotherapy regimen

CAPOX is a preferred first-line regimen for advanced gastric and colorectal cancers, supported by extensive guideline recommendations and clinical evidence demonstrating comparable efficacy to infusional fluorouracil-based regimens with the added convenience of oral administration.

Clinical Context and Indications

CAPOX is recommended across multiple cancer types:

For Gastric Cancer

• CAPOX is a preferred first-line regimen for HER2-negative advanced gastric cancer 1
• Phase II trials concluded that capecitabine combined with oxaliplatin is active and well-tolerated as first-line therapy for advanced gastric cancer 1
• Meta-analyses show that oxaliplatin-based regimens significantly improved partial response rate, disease progression rate, and 1-year overall survival compared to cisplatin-based regimens 1
• For HER2-positive disease, trastuzumab can be added to CAPOX (oxaliplatin is preferred over cisplatin due to lower toxicity) 1

For Colorectal Cancer

• CAPOX (also called CapeOx or XELOX) is FDA-approved and guideline-recommended for metastatic colorectal cancer 2, 3, 4
• CAPOX demonstrated non-inferiority to FOLFOX in a randomized phase III trial of 2,034 patients, with similar median progression-free survival (8.0 vs 8.5 months) 2
• The regimen is used both as adjuvant therapy after curative resection and as first-line treatment for metastatic disease 4

Dosing Regimens

Standard CAPOX dosing:

• Oxaliplatin: 130 mg/m² IV on day 1
• Capecitabine: 1,000 mg/m² orally twice daily for 14 days (days 1-14)
• Cycle length: Every 3 weeks 1, 2, 5

For elderly/frail patients with gastroesophageal cancer:

• The GO2 phase III trial (n=514) demonstrated that low-dose CAPOX (60% of standard dose) was non-inferior in progression-free survival with significantly lower toxicities 1
• This reduced-dose regimen is specifically recommended for elderly and/or frail patients with advanced or metastatic disease 1

Efficacy Data

Gastric Cancer

• Phase II HERXO trial (HER2-positive gastric cancer): median PFS 7.1 months, median OS 13.8 months 1
• Objective response rate: 55% in first-line metastatic colorectal cancer 5
• Median time to progression: 7.7 months; median overall survival: 19.5 months in metastatic colorectal cancer 5

Colorectal Cancer

• Adjuvant setting: 3-year relapse-free survival of 75% in locally advanced rectal cancer 6
• Metastatic setting: Similar efficacy to FOLFOX with response rates of 41-55% 5

Toxicity Profile and Management

Common adverse events:

• Sensory neuropathy: Most common (58-85% all grades; grade 3/4 in 16-18%) 1, 7, 6
  • Oxaliplatin should be discontinued after 3 months of therapy or sooner for unacceptable neurotoxicity 2
  • Patients should not receive subsequent oxaliplatin until near-total resolution of neurotoxicity 2
• Hand-foot syndrome: More common with capecitabine than infusional 5-FU 2
• Diarrhea: Grade 3/4 in 26.6% 1
• Myelosuppression: Uncommon with CAPOX (grade 3/4 neutropenia only 7-8%) compared to FOLFOX 1, 5

Critical safety considerations:

• Avoid cold exposure during and immediately after oxaliplatin infusion due to acute cold-induced neuropathy 4
• Monitor renal function closely; patients with diminished creatinine clearance may require capecitabine dose modification 2
• Contraindicated in patients with platinum allergy 4

Real-World Tolerability

A 2025 single-institution study of 153 patients with localized colorectal cancer receiving CAPOX showed:

• Only 44.4% completed all planned cycles (34.6% among female patients) 8
• Grade ≥3 adverse events: 30.7% 8
• Hospitalization due to toxicity: 17.6% 8

This highlights the importance of:

• Careful patient selection
• Proactive supportive care
• Early dose modifications when toxicity develops
• More realistic expectations about treatment completion rates

Practical Algorithm for Use

Step 1: Confirm indication

• Advanced/metastatic gastric or colorectal cancer
• Adjuvant therapy for high-risk resected disease

Step 2: Assess patient eligibility

• ECOG performance status 0-2
• Adequate organ function (ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L, creatinine ≤1.5 × ULN)
• No platinum allergy
• No severe baseline neuropathy

Step 3: Select dose intensity

• Standard dose for fit patients
• 60% dose reduction for elderly/frail patients 1

Step 4: Add targeted therapy if indicated

• Trastuzumab for HER2-positive gastric cancer (oxaliplatin preferred over cisplatin) 1
• Bevacizumab for colorectal cancer 3
• Nivolumab for PD-L1 CPS ≥5 gastric cancer 1

Step 5: Monitor and modify

• Discontinue oxaliplatin after 3 months or at first sign of significant neuropathy
• Continue capecitabine until progression
• Dose-reduce capecitabine at earliest signs of hand-foot syndrome

Key Advantages Over Infusional Regimens

• No central venous catheter required (eliminates catheter-related complications)
• No infusion pump needed (improves quality of life)
• Similar efficacy to FOLFOX 2
• Lower myelosuppression compared to FOLFOX 5
• Preferred by patients and healthcare providers due to convenience 5

Common Pitfalls to Avoid

1. Continuing oxaliplatin beyond 3 months increases cumulative neurotoxicity without additional benefit
2. Failing to dose-reduce in elderly/frail patients leads to unnecessary toxicity
3. Not educating patients about cold avoidance during oxaliplatin treatment
4. Inadequate monitoring of renal function when using capecitabine
5. Delaying dose modifications for hand-foot syndrome until it becomes severe

CAPOX represents a well-established, evidence-based chemotherapy option with the significant practical advantage of oral administration while maintaining efficacy comparable to infusional regimens.